The Histone Deacetylase Inhibitor OBP-801 Exhibits Potent Anti-Tumor Activity Against Neuroblastoma

被引：0
|
作者：
Kaneda, Daisuke [1 ]
Kikuchi, Ken [1 ,2 ]
Yagyu, Shigeki [1 ]
Iehara, Tomoko [1 ]
Sakai, Toshiyuki [3 ]
Hosoi, Hajime [1 ]
机构：
[1] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto, Japan
[2] Uji Takeda Hosp, Dept Pediat, Kyoto, Japan
[3] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kyoto, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS6-1-2
引用
收藏
页码：S40 / S41
页数：2
相关论文
共 50 条
  • [1] The histone deacetylase inhibitor OBP-801 has in vitro/in vivo anti-neuroblastoma activity
    Kaneda, Daisuke
    Iehara, Tomoko
    Kikuchi, Ken
    Sugimoto, Yohei
    Nakagawa, Norio
    Yagyu, Shigeki
    Miyachi, Mitsuru
    Konishi, Eiichi
    Sakai, Toshiyuki
    Hosoi, Hajime
    PEDIATRICS INTERNATIONAL, 2022, 64 (01)
  • [2] Identification the Molecular Mechanisms that Explain a Novel Histone Deacetylase Inhibitor OBP-801 Sensitivity in Human Cancer
    Ooizumi, Y.
    Yamashita, K.
    Kazuko, Y.
    Igarashi, K.
    Kojima, K.
    Katoh, H.
    Yamanashi, T.
    Sato, T.
    Nakamura, T.
    Watanabe, M.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S206 - S206
  • [3] The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA
    Sugimoto, Yohei
    Katsumi, Yoshiki
    Iehara, Tomoko
    Kaneda, Daisuke
    Tomoyasu, Chihiro
    Ouchi, Kazutaka
    Yoshida, Hideki
    Miyachi, Mitsuru
    Yagyu, Shigeki
    Kikuchi, Ken
    Tsuchiya, Kunihiko
    Kuwahara, Yasumichi
    Sakai, Toshiyuki
    Hosoi, Hajime
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (10) : 1992 - 2000
  • [4] OBP-801, a novel histone deacetylase inhibitor, induces M-phase arrest and apoptosis in rhabdomyosarcoma cells
    Tomoyasu, Chihiro
    Kikuchi, Ken
    Kaneda, Daisuke
    Yagyu, Shigeki
    Miyachi, Mitsuru
    Tsuchiya, Kunihiko
    Iehara, Tomoko
    Sakai, Toshiyuki
    Hosoi, Hajime
    ONCOLOGY REPORTS, 2019, 41 (01) : 643 - 649
  • [5] The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
    A M Savino
    J Sarno
    L Trentin
    M Vieri
    G Fazio
    M Bardini
    C Bugarin
    G Fossati
    K L Davis
    G Gaipa
    S Izraeli
    L H Meyer
    G P Nolan
    A Biondi
    G Te Kronnie
    C Palmi
    G Cazzaniga
    Leukemia, 2017, 31 : 2365 - 2375
  • [6] The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
    Savino, A. M.
    Sarno, J.
    Trentin, L.
    Vieri, M.
    Fazio, G.
    Bardini, M.
    Bugarin, C.
    Fossati, G.
    Davis, K. L.
    Gaipa, G.
    Izraeli, S.
    Meyer, L. H.
    Nolan, G. P.
    Biondi, A.
    Kronnie, G. Te
    Palmi, C.
    Cazzaniga, G.
    LEUKEMIA, 2017, 31 (11) : 2365 - 2375
  • [7] A histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth with apoptosis in triple-negative breast cancer cells
    Ono, Hisako
    Sowa, Yoshihiro
    Iizumi, Yosuke
    Horinaka, Mano
    Taguchi, Tetsuya
    Sakai, Toshiyuki
    CANCER RESEARCH, 2018, 78 (13)
  • [8] The molecular mechanism of histone deacetylase inhibitor (HDACi) PCI-24781 mediating anti-tumor activity in neuroblastoma cells
    Zhan, Qing Lei
    Ngai, Sai Ming
    FASEB JOURNAL, 2013, 27
  • [9] THE HISTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) HAS A POTENT ANTI-TUMOR ACTIVITY AGAINST CRLF2 REARRANGED LEUKEMIA
    Savino, A. M.
    Sarno, J.
    Trentin, L.
    Vieri, M.
    Fazio, G.
    Bardini, M.
    Bugarin, C.
    Fossati, G.
    Davis, K.
    Gaipa, G.
    Meyer, L.
    Nolan, G.
    Biondi, A.
    te Kronnie, T.
    Palmi, C.
    Cazzaniga, G.
    HAEMATOLOGICA, 2016, 101 : 198 - 198
  • [10] Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors
    Heath, Elisabeth I.
    Weise, Amy
    Vaishampayan, Ulka
    Danforth, Dailan
    Ungerleider, Richard S.
    Urata, Yasuo
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 300 - 307
12345